Questions to ask your doctor!

#TCellLymphoma #BloodCancer #BloodCancersOncTalk2025

Now presenting: Dr. @yumengzhang2009 "Understanding T-Cell Lymphoma"

Don't miss it and join us here:
give.cancergrace.org/event/2025-b...

#BloodCancer #TCellLymphoma

T-Cell Lymphoma Therapeutics Market Size, Growth Report 2032 T-Cell Lymphoma Therapeutics Market is projected to register a CAGR of 7% to reach USD 3.26 Billion by the end of 2032, Global T-Cell Lymphoma Therapeutics Industry Type, Application

🧫🔬 Targeting rare cancers with bold science! T-cell lymphoma therapies are advancing lives. 💉❤️‍🩹
#CancerCare #TCellLymphoma #Immunotherapy #OncologyNews

www.marketresearchfuture.com/reports/t-ce...

END‐OF‐TREATMENT PET/CT COMPLETE REMISSION IS HIGHLY PROGNOSTIC IN NODAL PERIPHERAL T‐CELL LYMPHOMA: AN AUSTRALASIAN‐CANADIAN COLLABORATIVE STUDY Click on the article title to read more.

We're also showcasing our #18ICML posters:
-221, real-world data on end-of-treatment imaging #TCellLymphoma;
-390, Ki67 expression level in #FollicularLymphoma

See you June 18👋

@icmlugano.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social
#LymphomaResearch #ClinicalResearch #Registry

OncaSune The official website and shop of OncaSune. Find the latest content, buy merch, and support your favorite creator.

The announcement day has arrived. It is the kitsunium collection. All products featuring the kitsunium will be going towards my cancer care. Only available while getting care. Get it today @ oncasune-shop.fourthwall.com/en-usd #tcelllymphoma #vtuber #twitch #smallstreamer #iknowwhatimdoing #cancer

Hey everyone, just wanted to post my gofundme one more time. gofund.me/9f6b4500 . If you could share the link that'd be super helpful. I appreciate all the help I can get. #vtuber #cancer #tcelllymphoma #idkwhatimdoing

Incidence, Prognostic Factors, and Treatment Impact on Survival in Natural Killer/T-Cell Lymphoma: Population-Based Study in the United States Background: Natural killer (NK)/T-cell lymphoma (NKTL) is a rare malignancy of mature NK/T-cells, predominantly found in Asian and South/Central American populations, with limited studies conducted in Europe and the United States. Objective: The aim of this study is to present an overview of the incidence rate, demographic and clinical characteristics, treatment options, overall survival (OS), and factors influencing OS of NKTL in the United States. Methods: We utilized data from the Surveillance, Epidemiology, and End Results (SEER) 17 database to analyze NKTL cases recorded between 2000 and 2020. In a cohort of 1162 NKTL patients, we calculated the incidence rates and performed statistical analyses to evaluate OS, the effect of radiotherapy and chemotherapy on survival, and lymphoma-specific survival. Results: The mean annual incidence rate of NKTL in the United States was 0.067 per 100,000, with higher rates observed in men compared to women, and an increase noted with age. However, there has been no significant rise in incidence over recent years. Significant racial disparities were observed, with higher incidence rates in Non-Hispanic Asian or Pacific Islanders (NHAPI) and Hispanics. The median survival time for NKTL patients was 21 months, with a 5-year overall survival (OS) rate of 39.5%, which has shown improvement in recent years. Key independent prognostic factors impacting patient survival included age at diagnosis, clinical stage, nasal type presentation, presence of systemic symptoms, and treatment modality. Patients receiving combined radiotherapy and chemotherapy exhibited the best outcomes, with a median OS of 138 months and a 5-year OS rate of 58%. This survival benefit remained consistent even in stage I/localized nasal type patients, achieving a 5-year OS rate of 73.3%. Conclusions: The incidence of NKTL has remained stable in recent years. Patients with the nasal type generally experience better survival outcomes. The use of combined radiotherapy and chemotherapy appears to enhance survival, though further validation through prospective multicenter clinical trials is necessary.

JMIR Formative Res: Incidence, Prognostic Factors, and Treatment Impact on Survival in Natural Killer/T-Cell Lymphoma: Population-Based Study in the United States #NaturalKillerCells #TCellLymphoma #CancerResearch #Oncology #SurvivalRates

#CancerResearch #TCellLymphoma #CARTCellTherapy #MedNewsWeek #Oncology #InnovativeTherapies

Rare side effect of cancer immunotherapy – BioNews Central A clinical case report provides important genetic insights into the development of T cell lymphoma following cancer immunotherapy for multiple myeloma. ...

A clinical #CaseReport provides important #genetic insights into the development of #TCellLymphoma following #Immunotherapy for #MultipleMyeloma.
#CancerImmunotherapy #CARTCellTherapy

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label,... In patients with heavily pretreated T-cell lymphoma, CTX130 showed manageable safety and a promising objective response rate. This study shows that allogeneic, readily available CAR T cells can be saf...

www.thelancet.com/journals/lan...

#CARTherapy #TcellLymphoma #ClinicalResearch #MedicalAdvances #celltherapy #immunotherapy #IO #genetherapy #allogeneic 📚